Pharmachem Announces New Studies

Pharmachem Announces New Studies

Study Update: All-Natural Starch Neutralizer Decreases Starch Absorption, Promotes Weight Loss

KEARNY, N.J.--Pharmachem Laboratories announced one completed study and the launch of additional clinical studies on its starch "neutralizer" product, Phase 2™. The new studies include an LD50 for chronic toxicity; a randomized, double blind, placebo-controlled weight loss trial; and a starch absorption study involving a full mixed meal. The completed study explored the LD50 for acute toxicity and found that there was no mortality when rats were fed various doses of Phase 2 for 14 days.

The new weight-loss trial will examine the impact of Phase 2 on weight and body fat percentage in 70 obese individuals. Jay Udani, M.D., will conduct the study at Northridge Hospital in Northridge, Calif., in conjunction with the University of California, Los Angeles. According to Udani, the study will also include full blood profiles, including total lipids and HBA1C, a marker of diabetes or insulin resistance. The starch absorption study follows two previous studies that showed Phase 2 significantly reduced starch absorption in humans given a high-fat, high-carbohydrate meal.

Details on the two studies will be presented during a VendorWorks presentation at SupplySide East. The seminar will take place from 10 to 10:50 a.m. on Tuesday, May 7. For more information, visitwww.pharmachemlabs.com.